Skip to content
For US Healthcare Professionals Patient Site
Picture of LEMTRADA patient Luis. Picture of LEMTRADA patient Luis.
Luis
38
El Paso, TX
married, father of 3, volunteer volleyball coach
“Relapsing MS has made it difficult for me to be as involved in my daughters' lives as I want to be.”

DISEASE HISTORY

7 Years

since RMS diagnosis

PATIENT BACKGROUND

RMS Risk Factors

male, worsening disability progression

RMS TREATMENT HISTORY

2 prior DMTs:
2 injectables

WHAT MOTIVATED YOU TO EXPLORE OTHER TREATMENT OPTIONS?

As a man, I know I am at risk for a worsening form of relapsing MS. Despite being on other treatments, I was experiencing multiple relapses that resulted in disability progression.

WHY CONSIDER LEMTRADA?

Things were getting worse for me, and it was important that I explored other therapy options that could possibly address my RMS. My doctor and I spent a lot of time discussing LEMTRADA pros and cons, and ultimately I felt that it was the right therapy for me given my active disease.

WHO PLAYED A ROLE IN YOUR DECISION?

My wife and I discussed with my neurologist potential side effects to look out for, such as certain types of cancers and infusion reactions. We talked about the monthly monitoring, too. My doctor is someone I can talk honestly to, and she helped me to prepare for treatment, so my overall experience was what I expected.

WHAT WOULD YOU SAY TO SOMEONE CONSIDERING SWITCHING?

Was I nervous? Was my family nervous? Of course. It’s normal to be nervous. Make sure you have open and honest conversations with your healthcare team and your family. Ask all your questions, even the ones you think are minor.

Are your patients interested in learning
more about LEMTRADA?

Download the full patient resource

INDICATION

LEMTRADA is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include relapsing-remitting disease and active secondary progressive disease, in adults. Because of its safety profile, the use of LEMTRADA should generally be reserved for patients who have had an inadequate response to two or more drugs indicated for the treatment of MS.

Limitations of Use: LEMTRADA is not recommended for use in patients with clinically isolated syndrome (CIS) because of its safety profile.

IMPORTANT SAFETY INFORMATION

WARNING: AUTOIMMUNITY, INFUSION REACTIONS, STROKE AND MALIGNANCIES

CONTRAINDICATIONS

LEMTRADA is contraindicated in patients:

WARNINGS AND PRECAUTIONS

Most Common Adverse Reactions

In controlled clinical trials, the most common adverse reactions (incidence ≥10% and >interferon beta-1a) with LEMTRADA vs interferon beta-1a were: rash (53% vs 6%), headache (52% vs 23%), pyrexia (29% vs 9%), nasopharyngitis (25% vs 19%), nausea (21% vs 9%), urinary tract infection (19% vs 8%), fatigue (18% vs 13%), insomnia (16% vs 15%), upper respiratory tract infection (16% vs 13%), herpes viral infection (16% vs 3%), urticaria (16% vs 2%), pruritus (14% vs 2%), thyroid gland disorders (13% vs 3%), fungal infection (13% vs 4%), arthralgia (12% vs 9%), pain in extremity (12% vs 9%), back pain (12% vs 8%), diarrhea (12% vs 6%), sinusitis (11% vs 8%), oropharyngeal pain (11% vs 5%), paresthesia (10% vs 8%), dizziness (10% vs 5%), abdominal pain (10% vs 5%), flushing (10% vs 4%), and vomiting (10% vs 3%).

Use in Specific Populations

Physicians are encouraged to report pregnancies by calling 1-800-745-4447, option 2. Antibodies, including anti-CD52 and autoantibodies, may be transferred from the mother to the fetus during pregnancy. Placental transfer of anti-thyroid antibodies resulting in neonatal Graves’ disease has been reported.

Safety and effectiveness in pediatric patients less than 17 years of age have not been established. Use of LEMTRADA is not recommended in pediatric patients due to the risks of autoimmunity and infusion reactions, stroke, and because it may increase the risk of malignancies.

Please see full Prescribing Information, including Boxed WARNING.

Indication

LEMTRADA is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include relapsing-remitting disease and active secondary progressive disease, in adults. Because of its safety profile, the use of LEMTRADA should generally be reserved for patients who have had an inadequate response to two or more drugs indicated for the treatment of MS.

Limitations of Use: LEMTRADA is not recommended for use in patients with clinically isolated syndrome (CIS) because of its safety profile.

IMPORTANT SAFETY INFORMATION

WARNING: AUTOIMMUNITY, INFUSION REACTIONS, STROKE AND MALIGNANCIES

  • LEMTRADA causes serious, sometimes fatal, autoimmune conditions such as immune thrombocytopenia and anti-glomerular basement membrane (anti-GBM) disease. Monitor complete blood counts with differential, serum
Alternate Text